Christian Chabannon

Summary

Affiliation: Institut Paoli-Calmettes
Country: France

Publications

  1. ncbi request reprint Transient detection of beta-galactosidase activity in hematopoietic cells, following reinjection of retrovirally marked autologous blood progenitors in patients with breast or ovarian cancer receiving high-dose chemotherapy
    Claude Bagnis
    Institut Paoli Calmettes, Centre Régional de Lutte Contre le Cancer Provence Alpes Côte d Azur, Marseille, France
    Exp Hematol 30:108-15. 2002
  2. ncbi request reprint [Immunotherapy with allogeneic haematopoietic stem cell transplantation: current status and perspectives]
    M Mohty
    Unite de Transplantation et de Therapie Cellulaire, Departement d Hematologie, Institut Paoli Calmettes, 232, Boulevard, Sainte Marguerite, 13273 Marseille Cedex 09, France
    Rev Med Interne 26:33-40. 2005
  3. ncbi request reprint Reduced intensity conditioning prior to allogeneic stem cell transplantation for patients with acute myeloblastic leukemia as a first-line treatment
    Didier P Blaise
    Unite de Transplantation et de Therapie Cellulaire, Institut Paoli Calmettes, Marseille, France
    Cancer 104:1931-8. 2005
  4. ncbi request reprint Reduced-intensity preparative regimen and allogeneic stem cell transplantation for advanced solid tumors
    Didier Blaise
    UTTC, Institut Paoli Calmettes, 232 Bd Ste Marguerite, 13273 Marseille Cedex 09, France
    Blood 103:435-41. 2004
  5. doi request reprint Long-term outcome after allogeneic stem-cell transplantation with reduced-intensity conditioning in patients with multiple myeloma
    Jean El-Cheikh
    Unité de Transplantation et de Thérapie Cellulaire U2T, Institut Paoli Calmettes, Marseille, France
    Am J Hematol 88:370-4. 2013
  6. ncbi request reprint Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen
    Mohamad Mohty
    Unite de Transplantation et de Therapie Cellulaire, Institut Paoli Calmettes, Marseille, France
    Blood 102:470-6. 2003
  7. doi request reprint A conditioning platform based on fludarabine, busulfan, and 2 days of rabbit antithymocyte globulin results in promising results in patients undergoing allogeneic transplantation from both matched and mismatched unrelated donor
    Raynier Devillier
    Département d Onco Hématologie, Institut Paoli Calmettes, Unite de Transplantation et de Therapie Cellulaire, F 13273, Marseille, France Aix Marseille Université, F 13007, Marseille, France Inserm UMR1068, Centre de Recherche en Cancérologie de Marseille CRCM, F 13009, Marseille, France
    Am J Hematol 89:83-7. 2014
  8. doi request reprint Response to immunosuppressive treatment predicts outcome in patients with chronic graft-versus-host disease: a single-center analysis of longitudinal data
    Roberto Crocchiolo
    Institut Paoli Calmettes, Marseille, France
    Biol Blood Marrow Transplant 19:576-83. 2013
  9. doi request reprint Donor CD3(+) lymphocyte infusion after reduced intensity conditioning allogeneic stem cell transplantation: single-center experience
    Jean El-Cheikh
    Unite de Transplantation et de Therapie Cellulaire, Institut Paoli Calmettes, Marseille, France
    Exp Hematol 41:17-27. 2013
  10. doi request reprint Two days of antithymocyte globulin are associated with a reduced incidence of acute and chronic graft-versus-host disease in reduced-intensity conditioning transplantation for hematologic diseases
    Roberto Crocchiolo
    Department of Hematology and Medical Oncology, Paoli Calmettes Institute, Marseille, France
    Cancer 119:986-92. 2013

Detail Information

Publications69

  1. ncbi request reprint Transient detection of beta-galactosidase activity in hematopoietic cells, following reinjection of retrovirally marked autologous blood progenitors in patients with breast or ovarian cancer receiving high-dose chemotherapy
    Claude Bagnis
    Institut Paoli Calmettes, Centre Régional de Lutte Contre le Cancer Provence Alpes Côte d Azur, Marseille, France
    Exp Hematol 30:108-15. 2002
    ..The fate of genetically modified cells and their progeny was followed in vivo, after reinfusion in patients treated with high-dose chemotherapy for poor-prognosis breast or ovarian carcinomas...
  2. ncbi request reprint [Immunotherapy with allogeneic haematopoietic stem cell transplantation: current status and perspectives]
    M Mohty
    Unite de Transplantation et de Therapie Cellulaire, Departement d Hematologie, Institut Paoli Calmettes, 232, Boulevard, Sainte Marguerite, 13273 Marseille Cedex 09, France
    Rev Med Interne 26:33-40. 2005
    ..Allogeneic stem cell transplantation (allo-SCT) is the most widely used form of immunotherapy. The allogeneic immune effectors infused with the graft can recognize and eradicate the patients' tumoral cells...
  3. ncbi request reprint Reduced intensity conditioning prior to allogeneic stem cell transplantation for patients with acute myeloblastic leukemia as a first-line treatment
    Didier P Blaise
    Unite de Transplantation et de Therapie Cellulaire, Institut Paoli Calmettes, Marseille, France
    Cancer 104:1931-8. 2005
    ..Thirty-three patients (median age 52; range 26-60) with acute myeloblastic leukemia (AML) were included in a pilot study of allogeneic stem cell transplantation (Allo-SCT) following a reduced-intensity conditioning (RIC)...
  4. ncbi request reprint Reduced-intensity preparative regimen and allogeneic stem cell transplantation for advanced solid tumors
    Didier Blaise
    UTTC, Institut Paoli Calmettes, 232 Bd Ste Marguerite, 13273 Marseille Cedex 09, France
    Blood 103:435-41. 2004
    ..Further studies are warranted in patients with less advanced ST...
  5. doi request reprint Long-term outcome after allogeneic stem-cell transplantation with reduced-intensity conditioning in patients with multiple myeloma
    Jean El-Cheikh
    Unité de Transplantation et de Thérapie Cellulaire U2T, Institut Paoli Calmettes, Marseille, France
    Am J Hematol 88:370-4. 2013
    ..After 10 years, the OS and PFS were 32% and 24%, respectively. The PFS curve after Allo-SCT stabilizes in time with a plateau after 6 years post Allo-SCT...
  6. ncbi request reprint Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen
    Mohamad Mohty
    Unite de Transplantation et de Therapie Cellulaire, Institut Paoli Calmettes, Marseille, France
    Blood 102:470-6. 2003
    ..Collectively, these results provide a framework for the refinement of RIC approaches designed to enhance the GVT effect with an acceptable risk of GVHD...
  7. doi request reprint A conditioning platform based on fludarabine, busulfan, and 2 days of rabbit antithymocyte globulin results in promising results in patients undergoing allogeneic transplantation from both matched and mismatched unrelated donor
    Raynier Devillier
    Département d Onco Hématologie, Institut Paoli Calmettes, Unite de Transplantation et de Therapie Cellulaire, F 13273, Marseille, France Aix Marseille Université, F 13007, Marseille, France Inserm UMR1068, Centre de Recherche en Cancérologie de Marseille CRCM, F 13009, Marseille, France
    Am J Hematol 89:83-7. 2014
    ..We conclude that the FBx-ATG regimen results in low incidences of NRM and GVHD in both MUD and the MMUD recipients...
  8. doi request reprint Response to immunosuppressive treatment predicts outcome in patients with chronic graft-versus-host disease: a single-center analysis of longitudinal data
    Roberto Crocchiolo
    Institut Paoli Calmettes, Marseille, France
    Biol Blood Marrow Transplant 19:576-83. 2013
    ..Further confirmation from larger studies is needed...
  9. doi request reprint Donor CD3(+) lymphocyte infusion after reduced intensity conditioning allogeneic stem cell transplantation: single-center experience
    Jean El-Cheikh
    Unite de Transplantation et de Therapie Cellulaire, Institut Paoli Calmettes, Marseille, France
    Exp Hematol 41:17-27. 2013
    ....
  10. doi request reprint Two days of antithymocyte globulin are associated with a reduced incidence of acute and chronic graft-versus-host disease in reduced-intensity conditioning transplantation for hematologic diseases
    Roberto Crocchiolo
    Department of Hematology and Medical Oncology, Paoli Calmettes Institute, Marseille, France
    Cancer 119:986-92. 2013
    ..ATG plays a pivotal role in the prevention of graft-versus-host disease (GvHD), but it is associated with a higher relapse rate and an elevated incidence of infections when high doses are used...
  11. ncbi request reprint CD8+ T cell dose affects development of acute graft-vs-host disease following reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation
    Mohamad Mohty
    Unité de Transplantation et de Thérapie Cellulaire UTTC, Institut Paoli Calmettes, Marseille, France
    Exp Hematol 32:1097-102. 2004
    ..It has been shown that antithymocyte globulin (ATG) dose infused during RIC is a major determinant for the likelihood of developing aGVHD. The ATG modulation on aGVHD is likely related to in vivo T-cell depletion...
  12. doi request reprint Lenalidomide plus donor-lymphocytes infusion after allogeneic stem-cell transplantation with reduced-intensity conditioning in patients with high-risk multiple myeloma
    Jean El-Cheikh
    Unité de Transplantation et de Thérapie Cellulaire U2T, Institut Paoli Calmettes, Marseille, France
    Exp Hematol 40:521-7. 2012
    ..This combination should be evaluated further in a larger cohort of patients...
  13. doi request reprint Hematopoietic engraftment of XLA bone marrow CD34(+) cells in NOG/SCID mice
    Thomas Moreau
    Institut Paoli Calmettes, Centre de Thérapie Cellulaire et Génique, Marseille, France
    Cytotherapy 11:198-205. 2009
    ....
  14. doi request reprint Acute GVHD is a strong predictor of full donor CD3+ T cell chimerism after reduced intensity conditioning allogeneic stem cell transplantation
    Jean El-Cheikh
    Unité de Transplantation et de Thérapie Cellulaire U2T, Département d Onco Hématologie, Institut Paoli Calmettes, Marseille, France
    Am J Hematol 87:1074-8. 2012
    ..However, chimerism testing could represent an attractive modality for minimal residual disease detection or for impeding relapse warranting further prospective studies...
  15. doi request reprint Reduced-intensity conditioning with Fludarabin, oral Busulfan, and thymoglobulin allows long-term disease control and low transplant-related mortality in patients with hematological malignancies
    Didier Blaise
    Unite de Transplantation et de Therapie Cellulaire, Institut Paoli Calmettes, 232 Boulevard Sainte Marguerite, Marseille, France
    Exp Hematol 38:1241-50. 2010
    ..No randomized controlled trials have been performed resulting in determining effectiveness on phase II studies, which rarely report on long-term survival...
  16. ncbi request reprint Bone marrow as stem cell source for allogeneic HLA-identical sibling transplantation following reduced-intensity preparative regimen
    Catherine Faucher
    Unité de Transplantation et de Thérapie Cellulaire UTTC, Institut Paoli Calmettes, Marseille, France
    Exp Hematol 31:873-80. 2003
    ..RIC has been shown to allow engraftment with minimal early transplant-related mortality (TRM). However, in the context of RIC, the use of bone marrow (BM) as stem cell source is still little evaluated...
  17. doi request reprint Randomized study of 2 reduced-intensity conditioning strategies for human leukocyte antigen-matched, related allogeneic peripheral blood stem cell transplantation: prospective clinical and socioeconomic evaluation
    Didier Blaise
    Transplant Program, Hematology Department, Paoli Calmettes Institute, Marseille, France
    Cancer 119:602-11. 2013
    ..The optimal intensity of reduced-intensity conditioning (RIC) before allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains uncertain...
  18. doi request reprint Comparable outcomes between unrelated and related donors after reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation in patients with high-risk multiple myeloma
    Jean El-Cheikh
    Unité de Transplantation et de Thérapie Cellulaire U2T, Institut Paoli Calmettes, Marseille, France
    Eur J Haematol 88:497-503. 2012
    ..241). In conclusion, these results suggest that URD in MM is feasible. The small number of patients with URD emphasizes the need to delineate indications and perform prospective protocols...
  19. pmc CD146 expression is associated with a poor prognosis in human breast tumors and with enhanced motility in breast cancer cell lines
    Gwladys Zabouo
    Institut Paoli Calmettes, Centre de Ressources Biologiques en Oncologie, Centre de Thérapie Cellulaire et Génique, Marseille, France
    Breast Cancer Res 11:R1. 2009
    ..Studies of CD146 expression and function in breast cancer remain scarce except for a report concluding that CD146 could act as a tumor suppressor in breast carcinogenesis...
  20. pmc Are there candidates for high-dose chemotherapy in ovarian carcinoma?
    Renaud Sabatier
    Department of Medical Oncology, Institut Paoli Calmettes, 232 Bd Ste Marguerite, Marseille 13273, France
    J Exp Clin Cancer Res 31:87. 2012
    ..Prognosis of advanced ovarian carcinomas (AOC) remains poor with a 5-year survival of 30%. Benefit from high-dose chemotherapy (HDC) in this disease has not been demonstrated to date...
  21. ncbi request reprint CD99 expressed on human mobilized peripheral blood CD34+ cells is involved in transendothelial migration
    Anne Marie Imbert
    Centre de Thérapie Cellulaire et Génique, Institut Paoli Calmettes, Centre Régional de Lutte Contre le Cancer Provence Alpes Côte d Azur, 232 Boulevard Sainte Marguerite, 13273 Marseille Cedex 9, France
    Blood 108:2578-86. 2006
    ..We conclude that expression of CD99 on human CD34+ progenitors has functional significance and that CD99 may be involved in transendothelial migration of progenitors...
  22. pmc Prognostic impact of hormone receptor- and HER2-defined subtypes in inflammatory breast cancer treated with high-dose chemotherapy: a retrospective study
    Laurys Boudin
    Departement d Oncologie Medicale, Institut Paoli Calmettes IPC, Marseille, F 13273, France Département d oncologie médicale, Hopital d Instruction des Armees Sainte Anne, Toulon, 83000, France
    J Cancer 7:2077-2084. 2016
    ..These findings provide additional information and options for patients with IBC and who could potentially benefit of HDC-AHSCT...
  23. doi request reprint National Institutes of Health classification for chronic graft-versus-host disease predicts outcome of allo-hematopoietic stem cell transplant after fludarabine-busulfan-antithymocyte globulin conditioning regimen
    Colombe Saillard
    Hematology Department, Institut Paoli Calmettes, Marseille, France
    Leuk Lymphoma 55:1106-12. 2014
    ..04) but comparable relapse risk (p = NS). In conclusion, the NIH classification appears to be more accurate in predicting outcome mostly by the reclassification of old-defined extensive forms into NIH-defined moderate or severe. ..
  24. doi request reprint Platelet recovery and transfusion needs after reduced intensity conditioning allogeneic peripheral blood stem cell transplantation
    Thomas Prebet
    Unité de Transplantation et de Thérapie Cellulaire UTTC, Departement d Hematologie, Institut Paoli Calmettes, Marseille Cedex, France
    Exp Hematol 38:55-60. 2010
    ..The aim of this retrospective study was to assess platelet transfusion needs and the kinetics and predictive factors for platelet recovery after reduced-intensity conditioning (RIC) allogeneic hematopoietic stem cell transplantation (HSCT)...
  25. pmc Protein profiling of human breast tumor cells identifies novel biomarkers associated with molecular subtypes
    Anthony Goncalves
    Department of Molecular Pharmacology, Marseille Research Cancer Center, Marseille, France
    Mol Cell Proteomics 7:1420-33. 2008
    ..Our study shows the potential of integrated genomics and proteomics profiling to improve molecular knowledge of complex tumor phenotypes and identify biomarkers with valuable diagnostic or prognostic values...
  26. ncbi request reprint Occurrence and severity of adverse events after autologous hematopoietic progenitor cell infusion are related to the amount of granulocytes in the apheresis product
    Boris Calmels
    Centre de Thérapie Cellulaire et Génique, Institut Paoli Calmettes, Centre Régional de Lutte Contre le Cancer Provence Alpes Côte d Azur, 13273 Marseille Cedex 9, France
    Transfusion 47:1268-75. 2007
    ..These reactions have traditionally been associated with the amount of infused cryoprotectant, but persistence of such events after dimethyl sulfoxide (DMSO) depletion has questioned this assumption...
  27. pmc Impact of pretransplant donor and recipient cytomegalovirus serostatus on outcome for multiple myeloma patients undergoing reduced intensity conditioning allogeneic stem cell transplantation
    Jean El-Cheikh
    Unité de Transplantation et de Thérapie Cellulaire U2T, Institut Paoli Calmettes, Marseille, France Département d Onco Hématologie, Institut Paoli Calmettes, Marseille, France
    Mediterr J Hematol Infect Dis 5:e2013026. 2013
    ..Novel prophylactic measures such as immunotherapy and drug prophylaxis need to be considered in this group of patients, warranting further prospective studies...
  28. doi request reprint [Perception by cancer patients of biomedical research in the era of large-scale biobanking]
    Julien Mancini
    Aix Marseille Univ, UMR 912, 13009, Marseille, France
    Med Sci (Paris) 28:28-32. 2012
    ..Patients are globally expressing a wish for more proposals to participate in research in collaboration with scientific teams...
  29. ncbi request reprint [Immunotherapy of acute myeloid leukemias: development of vaccines and cell therapy approaches]
    Mohamad Mohty
    Laboratoire d Immunologie des Tumeurs, Institut Paoli Calmettes, Centre Régional de Lutte Contre le Cancer Provence Alpes Côte d Azur, 232, boulevard de Sainte Marguerite, 13273 Marseille, France
    Bull Cancer 90:751-7. 2003
    ..We here review recently published observations in this field, and propose new vaccine programs that use autologous AML blasts differentiated into dendritic cells...
  30. doi request reprint The efficacy and safety of a new reduced-toxicity conditioning with 4 days of once-daily 100 mg/m(2) intravenous busulfan associated with fludarabine and antithymocyte globulins prior to allogeneic stem cell transplantation in patients with high-risk myel
    Anne Wanquet
    a Département d Onco Hématologie, Institut Paoli Calmettes, Marseille, France
    Leuk Lymphoma 57:2315-20. 2016
    ..NRM was 3% and 17% at day 100 and 1 year, respectively. This RTC conditioning regimen can lead to a long-term disease control. Moreover, it appears to be safe with a low NRM rate among high-risk patients. ..
  31. doi request reprint Haploidentical T Cell-Replete Transplantation with Post-Transplantation Cyclophosphamide for Patients in or above the Sixth Decade of Age Compared with Allogeneic Hematopoietic Stem Cell Transplantation from an Human Leukocyte Antigen-Matched Related or U
    Didier Blaise
    Transplant and Cellular Therapy Unit, Institut Paoli Calmettes, Marseille, France Hematology Department, Institut Paoli Calmettes, Marseille, France Centre de Recherche en Cancérologie de Marseille CRCM, Marseille, France Aix Marseille University AMU, Marseille, France Electronic address
    Biol Blood Marrow Transplant 22:119-24. 2016
    ..We conclude that T cell-replete haplo-ID HSCT followed by post-transplantation high-dose- cyclophosphamide in patients over 55 years is associated with promising results, similar to MRD HSCT, and is deserving prospective evaluation...
  32. doi request reprint Poor outcome with nonmyeloablative conditioning regimen before cord blood transplantation for patients with high-risk acute myeloid leukemia compared with matched related or unrelated donor transplantation
    Raynier Devillier
    Hematology Department, Transplantation Program, Institut Paoli Calmettes, Marseille, France Aix Marseille Université, Marseille, France Inserm UMR 1068 Centre de Recherche en Cancérologie de Marseille, Marseille, France Electronic address
    Biol Blood Marrow Transplant 20:1560-5. 2014
    ..Attempts to improve leukemic control with UCB Allo-HSCT are warranted, as well as the evaluation of other alternative donors in this context. ..
  33. doi request reprint Function of Jam-B/Jam-C interaction in homing and mobilization of human and mouse hematopoietic stem and progenitor cells
    Marie Laure Arcangeli
    Centre de Recherche en Cancerologie de Marseille, INSERM, UMR1068, Marseille, France Institut Paoli Calmettes, Marseille, France Aix Marseille Université, Marseille, France CNRS, UMR7258, Marseille, France
    Stem Cells 32:1043-54. 2014
    ....
  34. doi request reprint Antithymocyte globulin in reduced-intensity conditioning regimen allows a high disease-free survival exempt of long-term chronic graft-versus-host disease
    Raynier Devillier
    Hematology Department, Transplantation Program, Institut Paoli Calmettes, Marseille, France Aix Marseille Université, Marseille, France Centre de Recherche en Cancérologie de Marseille CRCM, Marseille, France
    Biol Blood Marrow Transplant 20:370-4. 2014
    ..It represents a valuable platform for developing further post-transplantation strategies aimed at reducing the incidence of relapse, particularly in the setting of high-risk disease...
  35. doi request reprint The cell polarity PTK7 receptor acts as a modulator of the chemotherapeutic response in acute myeloid leukemia and impairs clinical outcome
    Thomas Prebet
    INSERM U891, Centre de Recherche en Cancerologie de Marseille, Marseille, France
    Blood 116:2315-23. 2010
    ....
  36. ncbi request reprint Current update on reduced intensity regimens for allogeneic stem cell transplantation
    Didier Blaise
    Institut Paoli Calmettes, 232 Boulevard de ste Marguerite, 13273, Marseille, Cedex, France
    Hematology 10:64-5. 2005
  37. ncbi request reprint Age at transplantation and outcome after autologous stem cell transplantation in elderly patients with multiple myeloma
    Jean El Cheikh
    Department of Transplantation, Institut Paoli Calmettes, U2T Marseille, 13009, France
    Hematol Oncol Stem Cell Ther 4:30-6. 2011
    ..Autologous stem cell transplantation (auto-SCT) after high-dose melphalan chemotherapy can result in a prolonged response duration and survival in patients under 65 years of age...
  38. ncbi request reprint Restriction of transgene expression to the B-lymphoid progeny of human lentivirally transduced CD34+ cells
    Thomas Moreau
    Centre de Thérapie Cellulaire et Génique, Institut Paoli Calmettes, Centre Régional de Lutte Contre le Cancer Provence Alpes Côte d Azur, Marseille, France
    Mol Ther 10:45-56. 2004
    ..Such B-lineage-specific lentiviral vectors may be useful for correcting inherited disorders that affect B-lymphoid cells or for deciphering the transcriptional program that controls B cell commitment and differentiation...
  39. pmc Positron emission tomography response at the time of autologous stem cell transplantation predicts outcome of patients with relapsed and/or refractory Hodgkin's lymphoma responding to prior salvage therapy
    Raynier Devillier
    Hematology Department, Transplantation and Cell Therapy Program, Institut Paoli Calmettes, Marseille, France
    Haematologica 97:1073-9. 2012
    ....
  40. ncbi request reprint Clinical experience with the delivery of thawed and washed autologous blood cells, with an automated closed fluid management device: CytoMate
    Claude Lemarie
    Center of Cellular and Genetic Therapy, Department of Oncohematology, Transplantation and Cellular Therapy Unit, Paoli Calmettes Institute, Marseille, France
    Transfusion 45:737-42. 2005
    ..The procedure allows for the reduction of infused dimethyl sulfoxide (DMSO) quantities and the performance of biologic controls on the infused cell product...
  41. doi request reprint A gene expression signature identifies two prognostic subgroups of basal breast cancer
    Renaud Sabatier
    Département d Oncologie Moléculaire, Centre de Recherche en Cancerologie de Marseille, UMR891 Inserm, Institut Paoli Calmettes, Marseille, France
    Breast Cancer Res Treat 126:407-20. 2011
    ..This signature could help define the prognosis, adapt the systemic treatment, and identify new therapeutic targets...
  42. doi request reprint Gene expression profile predicts outcome after anthracycline-based adjuvant chemotherapy in early breast cancer
    Francois Bertucci
    Département d Oncologie Moléculaire, Centre de Recherche en Cancerologie de Marseille, UMR891 Inserm, Institut Paoli Calmettes IPC, Marseille, France
    Breast Cancer Res Treat 127:363-73. 2011
    ..Our predictor refines the prediction of metastasis-free survival after adjuvant anthracycline-based CT and might help tailoring adjuvant CT regimens...
  43. doi request reprint Unrelated cord blood compared with haploidentical grafts in patients with hematological malignancies
    Jean El-Cheikh
    Transplantation and Cellular Therapy Unit U2T, Paoli Calmettes Institute, Marseille, France
    Cancer 121:1809-16. 2015
    ..The aim of the current retrospective study was to compare the outcome of patients after haplo and UCB grafts prepared using a nonmyeloablative conditioning regimen...
  44. pmc Reduced-toxicity conditioning prior to allogeneic stem cell transplantation improves outcome in patients with myeloid malignancies
    Claire Oudin
    Departement d Hematologie, Institut Paoli Calmettes, Marseille, France Aix Marseille University, Marseille, France
    Haematologica 99:1762-8. 2014
    ..This well-tolerated conditioning platform can lead to long-term disease control and offers possibilities of modulation according to disease stage or further development. ..
  45. pmc CD146 expression in human breast cancer cell lines induces phenotypic and functional changes observed in Epithelial to Mesenchymal Transition
    Anne Marie Imbert
    Institut Paoli Calmettes, Centre de Ressources Biologiques en Oncologie, Centre de Therapie Cellulaire, Marseille, France
    PLoS ONE 7:e43752. 2012
    ..Such modifications resemble Epithelial to Mesenchymal Transition (EMT). In breast cancer CD146 expression is associated with poor prognosis and enhanced motility...
  46. doi request reprint JAM-B regulates maintenance of hematopoietic stem cells in the bone marrow
    Marie Laure Arcangeli
    Centre de Recherche en Cancerologie de Marseille, Unité Mixle de Recherche, Marseille, France
    Blood 118:4609-19. 2011
    ....
  47. doi request reprint [Ikaros and erythropoiesis]
    Marilyne Dijon
    Institut Paoli Calmettes, Centre de Thérapie Cellulaire et Génique, INSERM, U891, CRCM, Equipe Recherche Clinique, Marseille, F 13009, France
    Med Sci (Paris) 24:1065-70. 2008
    ..At the same time, myeloid differentiation was slightly favoured thus suggesting that Ikaros could be involved in the control of the myeloid/erythroid commitment...
  48. pmc Manufacturing Natural Killer Cells as Medicinal Products
    Christian Chabannon
    CBT 1409 INSERM, Aix Marseille Univ, Institut Paoli Calmettes, AP HM, Marseille, France CRCM INSERM, CNRS, Aix Marseille Univ, Institut Paoli Calmettes, CRCM, Marseille, France
    Front Immunol 7:504. 2016
    ..In the present review, we will focus on the technological and regulatory challenges of NK cell manufacturing and discuss conditions in which these innovative cellular therapies can be brought to the clinic...
  49. doi request reprint Immunohistochemical subtypes predict survival in metastatic breast cancer receiving high-dose chemotherapy with autologous haematopoietic stem cell transplantation
    Laurys Boudin
    Departement d Oncologie Medicale, Institut Paoli Calmettes IPC, Marseille, F 13273, France
    Eur J Cancer 57:118-26. 2016
    ....
  50. ncbi request reprint The role of Ikaros in human erythroid differentiation
    Marilyne Dijon
    Centre de Thérapie Cellulaire et Génique, Institut Paoli Calmettes, Marseille, France
    Blood 111:1138-46. 2008
    ..We conclude that Ikaros is involved in human adult or fetal erythroid differentiation as well as in the commitment between erythroid and myeloid cells...
  51. doi request reprint Reconstitution of natural killer cells in HLA-matched HSCT after reduced-intensity conditioning: impact on clinical outcome
    Caroline Pical-Izard
    INSERM, U1068, Centre Recherche en Cancérologie de Marseille, Institut Paoli Calmettes, CNRS, UMR7258, Aix Marseille University, Marseille, France
    Biol Blood Marrow Transplant 21:429-39. 2015
    ..However, there is a prolonged persistence of functional defects, the correction of which positively correlates with clinical outcome...
  52. ncbi request reprint [G-CSF in oncology]
    Frederic Viret
    Departement d Oncologie Medicale, Institut Paoli Calmettes, 232, boulevard Sainte Marguerite, 13273 Marseille Cedex 09
    Bull Cancer 93:463-71. 2006
    ..This article reviews the data supporting the clearly clinical applications of CSFs in oncology...
  53. ncbi request reprint Potential application of gene therapy to X-linked agammaglobulinemia
    Thomas Moreau
    Centre de Thérapie Cellulaire et Génique, Institut Paoli Calmettes, Marseille, F 13009, France
    Curr Gene Ther 7:284-94. 2007
    ....
  54. doi request reprint A new single-platform method for the enumeration of CD34+ cells
    Claude Lemarie
    Centre de Thérapie Cellulaire et Génique, Institut Paoli Calmettes, Marseille, France
    Cytotherapy 11:804-6, 806.e1. 2009
    ..A major disadvantage was the absence of specific software for data analyses and presentation of results...
  55. doi request reprint Assessing the HLA diversity of cord blood units collected from a birth clinic caring for pregnant women in an ethnically diverse metropolitan area
    Jeremy Magalon
    Cell Therapy Facility, Institut Paoli Calmettes, Marseille Cord Blood Bank, Marseille Inserm CBT 510, Centre d Investigations Cliniques en Biothérapie, Marseille
    Transfusion 54:1046-54. 2014
    ....
  56. doi request reprint Impact of viable CD45 cells infused on lymphocyte subset recovery after unrelated cord blood transplantation in children
    Vincent Barlogis
    Department of Paediatric Haematology, Hôpital La Timone Enfants, Marseille, France
    Biol Blood Marrow Transplant 17:109-16. 2011
    ..Considering the ratio vCD45/TNC, this "immune recovery based" threshold corresponds to a higher cell dose than the minimum usually recommended dose for myelogenous engraftment. This may have important implication for UCB selection...
  57. ncbi request reprint Overexpression of dominant-negative Ikaros 6 protein is restricted to a subset of B common adult acute lymphoblastic leukemias that express high levels of the CD34 antigen
    Cecile Tonnelle
    Institut Paoli Calmettes, Centre Régional de Lutte Contre le Cancer Provence Alpes Côte d Azur, Marseille, France
    Hematol J 4:104-9. 2003
    ..Comparison of BII cells with high or normal levels of Ik6 shows a higher level of expression for the membrane stem cell antigen CD34 in the former, as detected with flow cytometry and confirmed with DNA arrays...
  58. ncbi request reprint Purification of monocytes from cryopreserved mobilized apheresis products by elutriation with the Elutra device
    Claude Lemarie
    The MD Anderson Cancer Center, Blood and Marrow Transplantation Department, Houston, Texas, USA
    J Immunol Methods 318:30-6. 2007
    ..It requires no pre-processing of the cell product before elutriation, and allows the generation of phenotypically mature DC in quantities that are compatible with a clinical use...
  59. doi request reprint Hepatitis B virus reactivation in HBsAg-negative patients is associated with emergence of viral strains with mutated HBsAg and reverse transcriptase
    Philippe Colson
    IHU Méditerranée Infection, Pôle des Maladies Infectieuses et Tropicales Clinique et Biologique, Fédération de Bactériologie Hygiène Virologie, Centre Hospitalo Universitaire Timone, Assistance Publique Hopitaux de Marseille, Marseille, France Aix Marseille Université, URMITE UM63 CNRS 7278 IRD 198 INSERM U1095, Facultes de Medecine et de Pharmacie, Marseille, France
    Virology 484:354-63. 2015
    ..Virological factors associated with hepatitis B virus reactivation (HBV-R), following chemotherapy for cancer in hepatitis B surface antigen (HBsAg)-negative patients, are not well known...
  60. doi request reprint [Academic cell therapy facilities are challenged by European regulation on advanced therapy medicinal products]
    Christian Chabannon
    Centre de Therapie Cellulaire, Département de Biologie du Cancer, Institut Paoli Calmettes, 232 Boulevard Sainte Marguerite, 13273 Marseille Cedex, France Aix Marseille Université AMU, Marseille, France Inserm centre d investigations cliniques en biothérapie CBT 510, Marseille, France
    Med Sci (Paris) 30:576-83. 2014
    ..This situation raises significant issues for historical as well as emerging operators in this moving field that are discussed thereafter. ..
  61. doi request reprint [New molecular targets and new clinical practices for hematopoietic stem cell mobilization]
    Christian Chabannon
    Institut Paoli Calmettes, centre de lutte contre le cancer Provence Alpes Côte d Azur, Centre de Therapie Cellulaire, Marseille Cedex, France
    Bull Cancer 98:951-61. 2011
    ....
  62. pmc Targeting natural killer cells and natural killer T cells in cancer
    Eric Vivier
    Centre d immunologie de Marseille Luminy, Universite d Aix Marseille, Marseille, France
    Nat Rev Immunol 12:239-52. 2012
    ..The rational use of these cells in cancer immunotherapies awaits a better understanding of their effector functions, migratory patterns and survival properties in humans...
  63. doi request reprint Consent for biobanking: assessing the understanding and views of cancer patients
    Julien Mancini
    Universite d Aix Marseille, Marseille, France
    J Natl Cancer Inst 103:154-7. 2011
    ..We conclude that the opt-in consent procedure is positively perceived by most patients but should be improved for a better understanding and possibly an even better adherence to the consent process...
  64. doi request reprint Sixteen-kinase gene expression identifies luminal breast cancers with poor prognosis
    Pascal Finetti
    UMR599 Inserm, Institut Paoli Calmettes, Laboratoire d Oncologie Moleculaire, Centre de Recherche en Cancerologie de Marseille, Marseille, France
    Cancer Res 68:767-76. 2008
    ..The identification of luminal A cases of poor prognosis should help select appropriate treatment, whereas the identification of a relevant kinase set provides potential targets...
  65. ncbi request reprint RNA extracted from blood samples with a rapid automated procedure is fit for molecular diagnosis or minimal residual disease monitoring in patients with a variety of malignant blood disorders
    Didier Bechlian
    Institut Paoli Calmettes, Biothèque, tumorothèque, Centre de Ressources Biologiques en Oncologie, Marseille, France, Réseau des Centres de Ressources Biologiques et Tumorothèques de l Agglomération Marseillaise, Marseille, France
    Biopreserv Biobank 7:123-8. 2009
    ..Increased costs of reagents and disposables used for automated techniques can be compensated by a decrease in human resource. ..
  66. ncbi request reprint [The consortium of Biological Resource Centres (BRC) and tumour cell and tissue banks in the Marseilles metropolitan area]
    Christian Chabannon
    Réseau des Centres de Ressources Biologiques et Tumorothèques de l Agglomération Marseillaise, Biothèque Tumorothèque, Institut Paoli Calmettes, Centre Regional de Lutte Contre le Cancer, Provence Alpes Cote d Azur, France
    Med Sci (Paris) 22:26-31. 2006
    ..Through these efforts, the ultimate goal is to adopt rules that define BRC, as defined by the Organization for Economic Co-operation and Development (OECD)...
  67. ncbi request reprint Ikaros gene expression and leukemia
    Cecile Tonnelle
    Centre de Thérapie Cellulaire et Génique, Institut Paoli Calmettes, Centre Régional de Lutte Contre le Cancer Provence Alpes Cĵte d Azur, Marseille, France
    Leuk Lymphoma 43:29-35. 2002
    ..Whether this is a cause or a consequence of the leukemic process remains speculative. Other human diseases however, provide examples of abnormal post-transcriptional regulations that have been further characterized...
  68. ncbi request reprint [Happy birthday, CD34!]
    Christian Chabannon
    Centre de Thérapie Cellulaire et Génique, Institut Paoli Calmettes, Centre Régional de Lutte Contre le Cancer Provence Alpes Côte d Azur, Marseille, France
    Med Sci (Paris) 21:503-6. 2005
    ..This review focuses on major aspects of CD34 biology...
  69. pmc DNAM-1 and PVR regulate monocyte migration through endothelial junctions
    Nicolas Reymond
    Institut National de la Santé et de la Recherche Médicale UMR599, Institut de Cancérologie de Marseille, IFR 137, 27 Bd Lei Roure, 13009 Marseille, France
    J Exp Med 199:1331-41. 2004
    ..Altogether, our results demonstrate that DNAM-1 regulates monocyte extravasation via its interaction with PVR expressed at endothelial junctions on normal cells...